Horizon Pharma plc Announces Second-Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Horizon Pharma (HZNP) PT Bumped to $30 at BMO Capital Amid 'Very Solid' Q2
August 8, 2016 3:44 PM EDTBMO Capital analyst Gary Nachman reiterated an Outperform rating and bumped his price target on Horizon Pharma (NASDAQ: HZNP) to $30.00 (from $29.00) following "very solid" 2Q with revenue of $257mn vs. BMO/consensus of $235mn/235mn. EPS was $0.62 vs. BMO/consensus of $0.50/0.50 using the old tax... More
Piper Jaffray Remains Bullish on Horizon Pharma (HZNP) Following 'Strong' Q2, PT Trimmed to $33
August 8, 2016 12:33 PM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating on Horizon Pharma (NASDAQ: HZNP) but trimmed his price target to $33.00 (from $34.00) following "strong" Q2 results. The firm is remaining bullish on the name.
Amsellem commented, "Horizon reported 2Q16 non-GAAP diluted EPS of $0.56... More
Horizon Pharma (HZNP) Tops Q2 EPS by 12c
August 8, 2016 7:02 AM EDTHorizon Pharma (NASDAQ: HZNP) reported Q2 EPS of $0.62, $0.12 better than the analyst estimate of $0.50. Revenue for the quarter came in at $257.4 million versus the consensus estimate of $234.88 million.
For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.
... More